| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.072 | 0.2 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.039 | 0.2 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | -0.044 | 0.2 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.065 | 0.2 |
| mRNA | MS-275 | gCSI | pan-cancer | AAC | -0.067 | 0.2 |
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | -0.082 | 0.2 |
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | -0.048 | 0.2 |
| mRNA | GW-2580 | GDSC1000 | pan-cancer | AAC | -0.043 | 0.2 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | -0.088 | 0.2 |
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | -0.049 | 0.2 |